This segment opens with foundational context on ALK-positive non-small cell lung cancer, establishing the clinical and scientific backdrop that makes this disease state — and its recent treatment advances — so compelling.
Long-Term Outcomes with Lorlatinib vs Crizotinib in ALK-Positive NSCLC: Insights from the 7-Year CROWN Study
This segment dives into two of the most practically important questions facing clinicians who manage ALK-positive NSCLC: how to optimally test for ALK rearrangements, and how to select among the growing number of first-line treatment options available today.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Nearly half of older adults with metastatic lung cancer never receive systemic therapy, study finds
2
Machine learning model predicts T2D risk up to 10 years before onset
3
FDA approves new Ebglyss maintenance dose for moderate to severe atopic dermatitis patients
4
Rebate and adherence concerns drive payer reluctance on GLP-1 obesity coverage
5